+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Remicade

  • ID: 4775306
  • Report
  • August 2018
  • Region: Global
  • 86 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Remicade (infliximab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis.

Remicade has also been granted orphan drug status for Kawasaki disease in Japan.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Remicade: Crohn's disease
Remicade: Axial spondyloarthritis
Remicade: Rheumatoid arthritis
Remicade: Psoriatic arthritis
Remicade: Ulcerative colitis
Remicade: Psoriasis

LIST OF FIGURES
Figure 37: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 19: The authors drug assessment summary of Humira in Crohn’s disease
Figure 6: Sales of filgotinib and upadacitinib across the US, Japan, and five major EU markets, by drug, 2016–25
Figure 20: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: The authors drug assessment summary of Alofisel in Crohn’s disease
Figure 18: Remicade for Crohn’s disease – SWOT analysis
Figure 3: The authors drug assessment summary of Alofisel in Crohn’s disease
Figure 6: Entyvio for Crohn’s disease – SWOT analysis
Figure 8: Humira for Crohn’s disease – SWOT analysis
Figure 24: The authors drug assessment summary of Tysabri in Crohn’s disease
Figure 11: Remicade for Crohn’s disease – SWOT analysis
Figure 33: Filgotinib for Crohn’s disease – SWOT analysis

LIST OF TABLES
Table 1: Remicade drug profile
Table 2: Remicade pivotal trial data in adult Crohn’s disease
Table 3: Remicade pivotal trial data in pediatric Crohn’s disease
Table 4: Remicade sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 5: Remicade drug profile
Table 15: Entyvio sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 7: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Table 8: Remicade drug profile
Table 9: Remicade late-phase trial data in rheumatoid arthritis
Table 10: Remicade drug profile
Table 11: Remicade pivotal trial data in psoriatic arthritis
Table 12: Remicade drug profile
Table 13: Remicade pivotal trial data in ulcerative colitis
Table 14: Remicade drug profile
Table 15: Remicade pivotal trial data in psoriasis
Table 16: Remicade ongoing late-phase clinical trials in psoriasis
Table 25: Etrolizumab drug profile
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll